LLY
Eli Lilly
Pharmaceuticals · Health Care
$1,409-0.11%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:02 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Mixed profile
Revenue CAGR, 3Y lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.
The profile score is 10 points higher since last quarter. Growth is 21 points higher. Momentum is 9 points higher.
Sector rank 15 of 46
In plain English
- Eli Lilly operates in Pharmaceuticals.
- Latest-year revenue was 65.2 billion.
- The profile score is 56, a Mixed profile. Growth is the strongest listed input.
This company's filings do not tag an operating income line, and no total-costs figure exists to derive one. Operating margin, ROIC, margin stability, net debt to EBITDA, interest cover and Altman Z are left blank rather than estimated. Net income, revenue and cash flow come from the filing as reported.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Now 46.0 times, 5-year median 52.4 times.
Line is the quarterly multiple. The band is the 25th to 75th percentile of that history. The dashed line is the median.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.